Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Miebach, E ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anaphylaxis; Enzyme replacement therapy; Hypersensitivity; Infusion reaction; Mucopolysaccharidoses

Indexed keywords

ANTIALLERGIC AGENT; GALSULFASE; IDURONATE 2 SULFATASE; N ACETYLGALACTOSAMINE 4 SULFATASE; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL PROTOCOL; ENZYME REPLACEMENT; FEMALE; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAROTEAUX LAMY SYNDROME; METHODOLOGY; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS; PREMEDICATION; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; ENZYME REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERSENSITIVITY; IDURONATE SULFATASE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MUCOPOLYSACCHARIDOSES; MUCOPOLYSACCHARIDOSIS I; MUCOPOLYSACCHARIDOSIS II; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; PREMEDICATION; RECOMBINANT PROTEINS;

EID: 71849093612     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47100     Document Type: Conference Paper

References (29)

1. Brady RO, Murray GJ, Oliver KL, Leitman SF, Sneller MC, Fleisher TA et al. Management of neutralizing antibody to Ceredase in a patient with Type 3 Gaucher disease. Pediatrics. 1997; 100: E11.
2. Brown AF. Therapeutic controversies in the management of acute anaphylaxis. J Accid Emerg Med. 1998; 15: 89-95.
3. Castaneda JA, Lim MJ, Cooper JD, Pearce DA. Immune system irregularities in lysosomal storage disorders. Acta Neuropathol. 2008; 115: 159-174.
4. Finger E, Scheinberg M. Development of serum sickness- like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol. 2007; 13: 94-95. (Pubitemid 46597676)
5. Gell PGH, Coombs RGA. Clinical aspects of immunology. Oxford: Blackwell Scientific Publications; 1963.
6. Germain DP, Kaneski CR, Brady RO. Mutation analysis of the acid β-glucosidase gene in a patient with Type 3 Gaucher disease and neutralizing antibody to alglucerase. Mutat Res. 2001; 483: 89-94. (Pubitemid 33000070)
7. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004; 2: 542-553. (Pubitemid 38834038)
8. Harmatz P, Giugliani R, Schwartz I, Guffon N, Leão Teles E, Miranda MC et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006; 148: 533-539.
9. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001; 56: 813-824. (Pubitemid 32800388)
10. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004; 113: 832-836. (Pubitemid 38608590)
11. Kakkis E, Lester T, Yang R, Tanaka C, Anand V, Lemontt J et al. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Proc Natl Acad Sci USA. 2004; 101: 829-834. (Pubitemid 38121043)
12. Lieberman P. The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. J Allergy Clin Immunol. 1990; 86: 684-686.
13. Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. 2005; 95: 217-226.
14. Lieberman P, Kemp SF, Oppenheimer J, Lang DM, Bernstein DI, Nicklas RA et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005; 115: S483-S523. (Pubitemid 40327251)
15. Mehl A, Wahn U, Niggemann B. Anaphylactic reactions in children: a questionnaire-based survey in Germany. Allergy. 2005; 60: 1440-1445. (Pubitemid 41476190)
16. Moss J, Mertes P-M. Anaphylactic and anaphylactoid reactions. In: Hall JB, Schmidt GA, Wood LDH (eds). Principles of critical care (http://www. accessmedicine. com/content/aspx?aID = 2281763). 3rd ed. New York: McGraw-Hill; 2008.
17. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM et al. A Phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006; 8: 465-473.
18. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3421-3452.
19. Ring J, Behrendt H. H1- and H2-antagonists in allergic and pseudoallergic diseases. Clin Exp Allergy. 1990; 20 (Suppl 2): 43-49.
20. Ring J, Behrendt H. Anaphylaxis and anaphylactoid reactions. Classification and pathophysiology. Clin Rev Allergy Immunol. 1999; 17: 387-399. (Pubitemid 30321021)
21. Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs. 2007; 67: 2697-2716. (Pubitemid 350224380)
22. Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2007; 62: 830-837. (Pubitemid 47037864)
23. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004; 351: 2203-17.
24. Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol. 2006; 117: 367-377. (Pubitemid 43190151)
25. Spraycar M. Stedman's medical dictionary, 26th ed. Baltimore, MD, USA: Williams & Walkins; 1995.
26. Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases.Ann AllergyAsthma Immunol. 2006; 97: 39-43. (Pubitemid 44156335)
27. Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother. 2005; 6: 489-506. (Pubitemid 40521085)
28. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, doubleblinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J Pediatr. 2004; 144: 581-588. (Pubitemid 38594757)
29. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N et al. Mucopolysaccharidosis Type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008; 167: 267-277.